Legal Challenge To First Japan Rituxan Biosimilar Dismissed
Executive Summary
First Japan legal ruling means biosimilar competition can continue to gnaw away at Rituxan, at least for now, as Chugai faces rising challenges to its mature oncology portfolio.
You may also be interested in...
Approval Positions Roxadustat As Japan HIF-PHI Pioneer
The latest batch of product approvals in Japan positions Astellas’s roxadustat as the pioneer in the country’s potentially large HIF-PH inhibitor market in anemia, while Takeda and Meiji Seika see other important approvals and the first biosimilar teriparatide receives a nod.
Chugai Expects Limited Impact From First Biosimilar To Top Seller
First biosimilar version of Avastin approved in Japan, posing the first direct threat to Chugai's top product. But indications and timings mean the company expects limited impact this year.
Oncology, Orphans Dominate Japan Fiscal 2018 Approvals
Oncology again dominated new drug approvals in Japan last fiscal year, when expedited and special review pathways also played a major role in ensuring early access to new therapies.